BP1HB
Asset Logo

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

5.439% Snr Gtd Nts Mat 28-Aug-34 Min Cons $5Ht Nc

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in BP1HB

0

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

N/A

πŸ’΅ Average investment amount

N/A

⏰ Last time a customer invested in BP1HB

N/A
BP1HB investor breakdown
πŸ’΅ Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

πŸ™‹ Legal gender of investors

Female

Male

Pearlers who invest in BP1HB also invest in...

Want more shares? Try these...

Bph Global Ltd

BP8

BPH Global Ltd. is a plant-based biotechnology company, which engages in the business of sourcing, producing, marketing, and selling traditional medicines. The company is headquartered in Melbourne, New South Wales. The company went IPO on 2000-06-13. The firm is focused on producing foods and products that deliver Traditional Chinese Medicine-based health outcomes. The company focuses on the research and development, production and commercialization of plant-based products, including seaweed and sea plants to produce sustainable plant-based protein foods and nutraceutical and pharmaceutical ingredients (including cannabidiol (CBD) extracted from Hemp) for utilization in the food, nutrition, healthcare, cosmetics, and personal care industries. Its principal business focus is on Singapore, Australia, Southeast Asia, and Chinese markets. The firm produces its products through various plants, which include Caulerpa lentillifera, Dendrobium officinale, Resina and Cannabis sativa. The company is also into the sales and distribution of bird's nest products in China. Its subsidiaries include Stemcell United Pte Ltd, Stemcell Essential Pte Ltd, and SCU Southeast Asia Sdn Bhd, SCU (HK) Ltd.

πŸ™Œ Performance (5Yr p.a)

-14.27%

πŸ“Š Share price

$0.00 AUD

🧬 BIOTECHNOLOGY

Find Out More

πŸ“Š Share price

$0.00 AUD

Botanix Pharmaceuticals Ltd. is a dermatology company, which engages in the business of researching and developing dermatology and antimicrobial products. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of treatments for common skin diseases and infections. Its lead product is Sofpironium Bromide, for the treatment of primary axillary hyperhidrosis. The company also has a pipeline of other products in late-stage clinical studies for the treatment of moderate to severe rosacea, dermatitis, and acne respectively. The company also developing a topical antimicrobial product for the eradication of bacteria on the skin surface, initially in patients who are undergoing hemodialysis. Its BTX1503 product is a transdermal gel formulation for the treatment of serious acne in adults and teenagers. Its BTX1702 product for the treatment of papulopustular rosacea. Its BTX 1204A canine study in Australia and New Zealand for atopic dermatitis. Its BTX1801 is an antimicrobial gel focused on targeting Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus.

πŸ™Œ Performance (5Yr p.a)

63.91%

πŸ“Š Share price

$0.36 AUD

πŸ“¦ LOGISTICS

Compare
Add to watchlist